The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: Results of a preplanned interim analysis of a prospective study.
L. Bergmann
Consultant or Advisory Role - Novartis
Honoraria - Novartis
U. Kube
No relevant relationships to disclose
M. Kindler
No relevant relationships to disclose
T. Koepke
No relevant relationships to disclose
G. Steiner
No relevant relationships to disclose
J. Janssen
No relevant relationships to disclose
S. Fries
No relevant relationships to disclose
P. Goebell
Honoraria - speech at study meeting
A. Jakob
Honoraria - Novartis
T. Steiner
Consultant or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; Pfizer
M. D. Staehler
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
F. Overkamp
No relevant relationships to disclose
M. Albrecht
Employment or Leadership Position - Novartis
C. Doehn
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline